News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Stealth Peptides Inc. Completes Initial Phase I Clinical Trial Cohort with BendaviaTM, a Mitochondrial Targeted Therapy for Ischemia Reperfusion Injury


6/14/2010 1:54:39 PM

ROCKVILLE, Md.--(BUSINESS WIRE)--Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative therapies, announced today that it concluded its initial Phase I clinical trial cohort of a first–in–humans study with Bendavia™, a compound that targets mitochondria to treat ischemia reperfusion injury. The Investigational New Drug (IND) application for Bendavia was approved by the U.S. Food and Drug Administration (FDA) during May 2010.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES